OliX Pharmaceuticals Inc
226950
Company Profile
Business description
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company’s pipeline products include OLX101, OLX201, OLX301, OLX102, and others.
Contact
No. 1014 Gwanggyo Ace Tower 1
Daehak 4-ro, Yeongtong-gu
Gyeonggi
Suwon16226
KORT: +82 317798400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
67
Stocks News & Analysis
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
Why earnings growth might be more important when assessing frothy market conditions.
stocks
Are negative AI narratives holding this ASX share back?
This company is unlikely to be disrupted by AI
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,986.20 | 49.10 | -0.54% |
| CAC 40 | 8,378.96 | 11.63 | 0.14% |
| DAX 40 | 24,919.16 | 292.27 | 1.19% |
| Dow JONES (US) | 52,182.74 | 306.63 | 0.59% |
| FTSE 100 | 10,556.28 | 72.06 | 0.69% |
| HKSE | 22,881.02 | 145.66 | -0.63% |
| NASDAQ | 25,820.14 | 522.53 | 2.07% |
| Nikkei 225 | 70,062.32 | 594.21 | 0.86% |
| NZX 50 Index | 13,621.66 | 76.10 | 0.56% |
| S&P 500 | 7,440.43 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,778.70 | 52.80 | -0.60% |
| SSE Composite Index | 4,094.40 | 20.50 | 0.50% |